Sobi Gains EU Approval for Rare Kidney Disease Treatment Aspaveli
Event summary
- Sobi received European Commission approval for Aspaveli (pegcetacoplan) to treat C3 glomerulopathy (C3G) and primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) in patients 12 years and older.
- Aspaveli is the first approved treatment for both C3G and primary IC-MPGN, and the first treatment for adolescent patients (12-17 years) with these conditions.
- The approval follows a positive opinion from the CHMP in December 2025 and is based on results from the Phase 3 VALIANT study.
- Approximately 8,000 people in Europe are affected by C3G or primary IC-MPGN, a population with limited treatment options and high risk of kidney failure.
The big picture
The approval of Aspaveli highlights the growing focus on rare diseases within the biopharmaceutical industry, driven by regulatory incentives and unmet medical needs. Sobi’s partnership with Apellis demonstrates a trend of collaboration to tackle complex drug development and commercialization challenges. The VALIANT trial results, published in the New England Journal of Medicine, underscore the importance of rigorous clinical evidence in securing regulatory approvals for novel therapies.
What we're watching
- Commercialization
- The speed of Aspaveli’s adoption will depend on physician familiarity with the disease and the drug’s novel mechanism, potentially requiring significant educational investment by Sobi.
- Market Dynamics
- Given the relatively small patient population (8,000 in Europe), Sobi will need to demonstrate a strong return on investment to justify the drug’s pricing and maintain its market exclusivity.
- Partner Alignment
- The co-development and commercialization agreement with Apellis will be critical; any disagreements over strategy or resource allocation could impact Aspaveli’s success.
Related topics